Re Facial aesthetic injections in clinical practice: Pretreatment and post-treatment consensus recommendations to minimise adverse outcome Region-specific changes in line with the Covid-19 pandemic.
Despite the recent publication in March 2020 of guidelines for facial injectable treatments, the speed of the COVID-19 pandemic and its safety implications necessitate changes to these guidelines The authors described what would constitute safest practice in the provision of facial injectable treatments and summarised these in table form. Adherence to a high standard of asepsis and infectious disease precautions remain a key patient safety requirement when performing facial aesthetic injections. A revision and update of these guideline summary tables follows. Changes made should enhance both patient and staff safety regarding COVID-19/SARS-CoV-2, a highly infective respiratory pathogen transmitted by respiratory droplets, respiratory/mucosal secretions and contaminated fomites. Some of the additions are COVID-19 specific and are likely to evolve and change, particularly should serological tests determining acquired immunity become available. Other additions represent further tightening of our infection control precautions.
['Goodman|Greg J|GJ|https://orcid.org/0000-0003-4089-9690', 'Liew|Steven|S|', 'Callan|Peter|P|', 'Hart|Sarah|S|', 'Somia|Naveen|N|', 'Sullivan|John|J|', 'Heydenrych|Izolda|I|']
D000554:Ambulatory Care Facilities D001905:Botulinum Toxins D000086382:COVID-19 D032921:Consensus D003357:Cosmetic Techniques D000067548:Dermal Fillers D003880:Dermatology D006801:Humans D017053:Infection Control D008403:Mass Screening D000067393:Personal Protective Equipment D017410:Practice Guidelines as Topic D000086402:SARS-CoV-2 D017216:Telemedicine
COVID-19 botulinum toxin hyaluronic acid tissue fillers